Inflammation associated with bacterial infections is a risk factor for cancers in humans, yet its role in breast cancer remains poorly understood. We have previously shown that innate immune inflammatory response against intestinal bacteria is sufficient to induce colon cancer. Here we report that infecting Rag2-deficient C57BL/6 Apc Min/+ mice with an intestinal bacterial pathogen, Helicobacter hepaticus, significantly promotes mammary carcinoma in females and enhances intestinal adenoma multiplicity by a tumor necrosis factor A (TNFA)-dependent mechanism. The mammary and intestinal tumor development as well as the increase in proinflammatory mediators is suppressed by adoptive transfer of interleukin 10-competent CD4 + CD45RB lo CD25 + regulatory (T R ) cells. Furthermore, prior exposure of donor mice to H. hepaticus significantly enhances antitumor potency of their T R cells. Interestingly, these microbially experienced T R cells suppress tumorigenesis more effectively in recipient mice irrespective of their tumor etiology. These data suggest that infections with enteric pathogens enhance T R -cell potency and protect against epithelial cancers later in life, potentially explaining paradoxical increases in cancer risk in developed countries having more stringent hygiene practices. The possibility that dysregulated gut microbial infections in humans may lead to cancer in anatomically distant organs, such as breast, highlights the need for novel immune-based strategies in cancer prevention and treatment. (Cancer Res 2006; 66(15): 7395-400) 
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Introduction
Chronic inflammation promotes carcinogenesis and predisposes susceptible individuals to cancer (1, 2) . In humans, infectious inflammation associated with prolonged activation of the host immune system by parasitic, viral, and bacterial agents has been shown to contribute to tumor formation at several sites including bladder (3), liver (4) , and stomach (5) . Similarly, inflammation of noninfectious nature has been associated with other types of cancer including colorectal cancer (6) , lung cancer (7) , and cancer of esophageal/gastric junction (8) . Breast cancer, the most frequently diagnosed cancer in North America, nearly thrice its rate in the developing world, has increasing incidence rate at f4% per annum over the past decade (9) . Despite intense efforts to understand etiopathogenesis of breast cancer, no clear explanation for its increasing incidence has been forthcoming.
Cancers of bowel (10) and breast (11) have been associated with mutations in adenomatosis polyposis coli (APC), the gene responsible for multiple intestinal neoplasia in humans and mice (12) . Mice heterozygous for Apc gene (Apc Min/+ ) develop a large number of intestinal polyps by 3 months of age (13) and this process has been shown to be inhibited by adoptive transfer of interleukin 10 (IL-10)-competent T R cells (14) . Despite their high predilection for intestinal tumors, unmanipulated C57BL/6 Apc Min/+ mice rarely show mammary tumors when housed in our specific pathogen-free animal facilities (15) , in contrast to higher tumor incidence reported previously in other animal facilities (13, 16) . We reasoned that inflammation induced in the gut by proinflammatory microbial infection could have systemic effects, which would then influence carcinogenic events in other organs including mammary gland. Here, we investigate whether Helicobacter hepaticus-triggered inflammatory responses modulate carcinogenesis in Apc Min/+ mice, using a widely applied adoptive T-cell transfer model (17) and recombination-activating gene 2 (Rag2)-deficient Apc Min/+ mice, and assess the roles for innate immune inflammatory response in mammary and intestinal tumor development.
Materials and Methods
Experimental animals. All animals were housed in Association for Assessment and Accreditation of Laboratory Animal Care-approved facilities and maintained according to protocols approved by the Institutional Animal Care and Use Committee at Massachusetts Institute of Technology. Apc Min/+ mice on a C57BL/6J background were originally obtained from The Jackson Laboratory and bred in house as heterozygous Â wild type crosses to provide Apc Min/+ mice and wild-type littermates for experimental recipients and donors. Before the study, Helicobacter-free status of the mice was confirmed by PCR using Helicobacter genus-specific primers as previously described (18) . Experimental H. hepaticus infection. A total of 71 experimental mice were dosed at 2 to 3 months of age with H. hepaticus and housed separately in a bio-containment area within the same animal facility. H. hepaticus (strain 3B1, ATCC 51449; ref. 19) was grown under microaerobic conditions, prepared, and confirmed pure as described elsewhere (20) . Experimental mice received 0.2 mL of fresh inoculum by gastric gavage every other day for a total of three doses. Cecum and colons were collected 3 to 4 weeks postinfection at necropsy and analyzed by PCR using H. hepaticus-specific primers to confirm experimental infection (18 + (T R ) lymphocytes were isolated from spleen and mesenteric lymph nodes and adoptively transferred as previously described (14) . The donor mice for T R cells included male and female H. hepaticus-infected or Helicobacter -free C57BL/6 mice or H. hepaticus-infected IL-10-deficient C57BL/6 mice. The T R -cell donors were dosed with H. hepaticus 8 weeks earlier. The recipients used in this study were all female mice, based on the earlier observation that mammary tumor incidence is greater in female mice (13) . Replicate experiments were conducted with two or three groups of similar size for select experiments.
Tumor necrosis factor A neutralization. 
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Min/+ mice, 3 to 4 months of age, were treated with IL-10-Ig fusion protein at 5 Ag per mouse twice weekly (2-3 days apart) for 1 week. To produce the IL-10-Ig fusion protein, genes for murine IL-10 and immunoglobulin G2a (IgG2a) CH2 were fused and the chimeric gene was cloned into an adenoviral vector and the infectious virus (AdIL-10Ig) was generated as described elsewhere (21) . Adv-IL-10Ig was used to infect Helicobacter-free Rag2-deficient B6 mice (10 11 virions per animal). Fusion protein from 10-DPI serum was quantified using an IgG2a-specific ELISA (150 ng/mL of IL-10-Ig = 1 ng/mL of recombinant IL-10 to suppress IL-12 p40 and IP-10 by IL-10-deficient macrophages). Serum containing the required dose of fusion protein was administered by i.p. injection to mice.
Quantitation of intestinal tumors. Location of tumors was recorded using a stereomicroscope at Â10 magnification. Location of tumors in the small intestine was recorded as distance from the pylorus to duodenum, jejunum, and ileum, comprising one third of small intestine each (14) .
Histologic evaluation. As previously described (15), the formalin-fixed tissues were processed and the H&E-stained tissue sections were evaluated by two veterinary pathologists blinded to sample identity. Macrophages were identified by standard avidin-biotin-complex immunohistochemistry using rat anti-mouse F4/80 and biotinylated goat anti-rat IgG (Serotec, Oxford, United Kingdom).
Detection of cytokine mRNA expression in colon and mammary tissue. The RNase protection assay to detect cytokine mucosal mRNA has been described in detail elsewhere (20) . Briefly, frozen specimens of cecocolic junction were homogenized into Tri-reagent (MRC, Cincinnati, OH) and RNA was prepared per instructions of the manufacturer. Ribonuclease protection assay analyses were done with 20 Ag of total RNA using RiboQuant Multi-Probe Template Sets (PharMingen, San Diego, CA). Intensities of the protected fragments were quantitated by phosphorimager analysis and normalized to internal controls as previously described (20) . TNFa mRNA levels in mammary tissue were measured using real-time quantitative PCR as previously described (14) .
Statistical analyses. Total tumor counts were analyzed by one-way ANOVA using Newman-Keuls posttest. Mammary tumor incidence was compared using contingency tables and m 2 analysis. Macrophage counts were compared by unpaired two-tailed t test. Small and large intestine tumor multiplicities were compared by unpaired t test with Welch's correction. For all statistical analyses, GraphPad Prism version 4.0 for windows (GraphPad Software, San Diego, CA) was used.
Results and Discussion
Innate immunity is sufficient for mammary and intestinal tumor development. Previously, we showed that the innate immune inflammatory response was sufficient to promote colorectal carcinoma in Rag2-deficient 129/SvEv mice (20, 22) . In the present study, we first sought to determine whether lymphocytes are essential for mammary and intestinal tumorigenesis in Apc Min/+ mice. We find that unmanipulated Rag2 À/À Apc Min/+ mice between 4 and 4.5 months of age develop significantly (P < 0.01) more frequent adenomas in the small bowel (Fig. 1A) (Fig. 2H) , consistent with inflammationassociated breast cancer in humans (23, 24) .
Similarly, we also find that Apc Min/+ mice (N = 11) infected with H. hepaticus showed an increase in the adenoma multiplicity in the small and large intestine ( Fig. 1 ; Table 1 ) when compared with Helicobacter-free age-matched controls. In addition, 63% (7 of 11; P < 0.001) of female Apc Min/+ mice that received H. hepaticus 4 to 6 weeks earlier had palpably enlarged mammary glands (Fig. 1B) with histologic features of adenosquamous mammary carcinoma (Fig. 2B ) when examined at 3 to 4 months of age. In contrast, no mammary tumors were found in Helicobacter-free Apc Min/+ females (0 of 8 animals) during the course of the study. Microscopically, the tumors in Apc Min/+ mice had more locally invasive borders and had increased squamification when compared with neoplastic mammary glands of Rag2 pathway (25) . One explanation for the frequency of H. hepaticusinduced tumors in Apc Min/+ may be the recently described immune deficits. Thymic atrophy and lymphopenia (26) may decrease T R cell competency in Apc Min/+ mice, thereby enabling uncontrolled activation of Helicobacter-primed T E cells (27) or other cells of adaptive immunity, which may promote mammary and intestinal carcinogenesis. Nonetheless, the observation that H. hepaticus infection promotes mammary tumors in both lines of mice raises the likelihood that proinflammatory intestinal bacterial infections contribute to breast tumorigenesis in other mouse models as well as in women.
H. hepaticus-triggered intestinal and mammary carcinoma is TNFa dependent. To examine whether H. hepaticus infection is accompanied by up-regulation of proinflammatory cytokines, we analyzed gut mucosal expression levels of cytokines including TNFa, IL-12p40, IFNg, and macrophage inflammatory protein 2 (MIP-2). We find increased expression of all four cytokines (Fig. 3 ) consistent with our prior findings in colitis and colon cancer (20) . Because TNFa is a key cytokine implicated in inflammationassociated cancers (28) , and treatment with anti-TNFa antibody has been shown to suppress polyp formation in Apc Min/+ mice (15), we asked whether the H. hepaticus-promoted tumorigenesis in Rag2
Min/+ is dependent on TNFa. Indeed, neutralization of TNFa by antibody significantly suppressed both intestinal (P < 0.001) and mammary tumors (P < 0.05; Fig. 1A and B) in the H. hepaticus-infected Rag2 À/À Apc Min/+ mice. Therapeutic 
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Min/+ mice. Columns, total number of mice within the group; shaded area, number of mice with mammary tumors. Tumor data were pooled from two independent experiments. C, T R cells from wild-type mice exposed to H. hepaticus showed greater potency in suppressing the intestinal tumors when compared with cells from naïve donor. A suboptimal dose of 1 Â 10 5 T R cells per mouse from H. hepaticus -infected (8 weeks earlier) wild-type mice suppressed more effectively intestinal tumors in Rag2 À/À
Min/+ mice. This potent tumor-suppressive effect by H. hepaticus -exposed T R cells was observed regardless of the recipient's infection status. Data represent total tumor counts in individual mice and the lines indicate means of tumor counts within each group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (20, 27) . To determine whether T R cells can inhibit Helicobacter-promoted tumorigenesis in Rag2 À/À Apc Min/+ , nine female mice, 2 to 3.5 months of age, were infected with H. hepaticus and adoptively transferred with 3 Â 10 5 cells per recipient of T R cells collected from Helicobacter-free wild-type donors. When examined 3 to 4 weeks later, we found a significant (P < 0.001) reduction in intestinal adenoma multiplicity (l = 14.8 F 3.69; Fig. 1A ) and observed no mammary tumors (P < 0.05) in these infected T R cell-recipient mice. Additionally, treatment of H. hepaticus-infected mice with T R cells resulted in a significant (P < 0.001) decrease in the levels of intestinal mucosal proinflammatory cytokines including TNFa and MIP-2 (Fig. 3 ). These 
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Min/+ mice. These findings match earlier data from our laboratory (14, 15) as well as by others (29) showing that T R cells are not only capable of regulating other T cells but are also capable of suppressing inflammation resulting from chronic activation of the innate immune system.
Prior challenge with H. hepaticus enhances antitumor potency of T R cells. Microbes or microbial products enhance survival, proliferation, and cytokine production by T R cells (30) . To test whether protective antitumor effects of T R cells can be enhanced by prior microbial challenge, we first determined a suboptimal dosage of 1 Â 10 5 CD45RB lo CD25 + wild-type T R cells per recipient (31) . We then used this lower dose of T R cells derived from donors that were infected at least 8 weeks earlier with H. hepaticus, or alternatively from donors that remained uninfected, for adoptive transfer into Rag2 À/À Apc Min/+ mice at time of infection with H hepaticus. We found that T R cells isolated from H. hepaticus-exposed donors were significantly (P < 0.001) more effective at suppressing H. hepaticus-induced intestinal tumors when compared with cells from naïve donors. It remains to be seen whether CD45RB To test whether the H. hepaticus-induced enhancement in antitumor potency of T R cells is limited to H. hepaticus-triggered tumors, the lower dosage of T R cells from H. hepaticus-infected as well as uninfected donors was transferred in parallel into Helicobacter -free Rag2 À/À Apc Min/+ recipients. We find that H. hepaticus-experienced T R cells are significantly (P < 0.001) more potent compared with cells from naïve donors (P < 0.05) at suppressing intestinal adenoma multiplicity in recipients that were not infected with H. hepaticus. The finding that tumor multiplicity is significantly inhibited by Helicobacter-challenged donor T R cells in all recipients irrespective of their Helicobacter status suggests that prior proinflammatory challenges broadly enhance antitumor potency of T R cells, even against tumors of unknown etiology. In light of recent studies showing that probiotic intestinal bacteria (32) and parasite antigens (33) enhance IL-10 and the protective functions of T R cells, it will be interesting to examine whether these agents will affect antitumor potency of T R cells in our model. IL-10 is critical to suppress H. hepaticus-promoted tumorigenesis. In murine models, CD4 + CD25 + regulatory (T R ) cells require anti-inflammatory cytokine IL-10 to inhibit inflammatory bowel disease (27, 31) , colon cancer (20, 22) , and intestinal polyposis (14) . To determine whether IL-10 is dispensable in T R cells endowed with microbially enhanced antitumor potency, we did adoptive transfer of T R cells from H. hepaticus-infected IL-10-deficient syngeneic donors into uninfected Rag2 , P < 0.001. Mice were either uninfected or dosed with H. hepaticus (Hh) and tumor multiplicity in small and large intestine was quantitated as described in Materials and Methods. Total tumor numbers in small and large intestine were separately analyzed between groups by using unpaired t test with Welch's correction using Prism 4.0 software as described in Materials and Methods. 
Min/+ mice. The intestinal mucosal expression levels of cytokines mRNA from uninfected, H. hepaticus -infected, and H. hepaticusinfected and T R cell (3 Â 10 5 )-treated mice are presented: A, IL-12p40; B, TNFa; TNFa; C, IFNg; and D, MIP-2. Infection with H. hepaticus significantly increased gene expression of all four cytokines analyzed. Adoptive transfer of wild-type T R cells significantly decreased expression of IFNg (P < 0.05), TNFa, and MIP-2 (both P < 0.001). Cytokine gene expression was analyzed by RNase protection and the intensity of the protected fragments was quantified after normalization to glyceraldehyde-3-phosphate dehydrogenase, which is used as internal control. Columns, mean relative mRNA expression for each cytokine from a group of six to eight mice; bars, SE. Data were analyzed and compared as described in Materials and Methods for statistical significance.
To determine whether exogenously administered IL-10 will inhibit mammary and intestinal tumors, we treated H. hepaticusinfected Rag2 À/À Apc Min/+ mice (N = 9) with IL-10-Ig fusion protein for 1 week. In all nine mice, we observed significantly (P < 0.001) fewer intestinal adenomas when compared with untreated infected control mice (Fig. 1A) . Likewise, when compared with the untreated group, only one of nine animals in the IL-10-Ig treated group had a mammary tumor (Fig. 1B) . These data support that IL-10 is sufficient to suppress tumors in the absence of lymphocytes. Although the cellular and molecular mechanism(s) through which IL-10 inhibits carcinogenesis are not well understood (34) , whether through suppression of inflammatory cytokines, promotion of epithelial homeostasis, or induction of toleragenic dendritic cells, the in vivo inhibitory effect(s) of IL-10-Ig on epithelial cancers in mice lacking lymphocytes is promising and may facilitate new studies in this area.
In summary, the study shows for the first time that an enteric microbial infection promotes cancer in the mammary gland. It is plausible that other proinflammatory bacteria including H. pylori also exert extraintestinal carcinogenic effects. Mammary tumor suppression by anti-inflammatory regimens in the present and prior study (15) 
